Search

Your search keyword '"Podoltsev NA"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Podoltsev NA" Remove constraint Author: "Podoltsev NA"
81 results on '"Podoltsev NA"'

Search Results

1. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2- mutant refractory/relapsed AML.

2. Analyzing determinants of premature trial discontinuation in leukemia clinical trials.

3. Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights.

4. Challenges in management of older patients with chronic myeloid leukemia.

5. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.

6. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia.

7. Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment.

8. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.

9. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.

10. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.

11. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia.

12. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.

13. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence.

14. Supportive Care for Patients With Myelodysplastic Syndromes.

15. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.

16. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.

17. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia.

18. Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome.

20. Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm.

23. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

24. Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy.

26. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States.

27. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.

28. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.

29. Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States.

30. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States.

31. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.

32. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.

33. Emerging agents and regimens for polycythemia vera and essential thrombocythemia.

34. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved.

35. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia.

36. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies.

37. A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance.

38. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

39. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission.

40. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.

41. Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort.

43. Clinical outcomes and characteristics of patients with TP53 -mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.

44. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study.

45. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.

47. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.

48. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.

49. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study † .

50. Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes.

Catalog

Books, media, physical & digital resources